Antares Pharma Appoints David H. Bergstrom Ph.D. as Senior Vice President Pharmaceutical Development

EWING, N.J. — Antares Pharma, Inc. (NASDAQ:ATRS) today announced the appointment of David H. Bergstrom Ph.D. to the position of Senior Vice President of Pharmaceutical Development. Dr. Bergstrom is an experienced, operations focused executive with a leadership background in large, small and semi-virtual pharmaceutical companies as well as in the contract product development and manufacturing industry. He received his Ph.D. in Pharmaceutics from the University of Utah, Salt Lake City, Utah.

Dr. Bergstrom comes to Antares Pharma from Advantar Laboratories where he was the Executive Vice President and Chief Operating Officer. Prior to joining Advantar, he was the Senior Vice President and COO for NovaDel Pharmaceuticals. Dr. Bergstrom previously served as Senior Vice President and General Manager of the Pharmaceutical Development business of Cardinal Health, Inc. Prior to Cardinal Health, Dr. Bergstrom served as Vice President of Pharmaceutical and Chemical Development at Guilford Pharmaceuticals and also served in senior positions in preclinical development and pharmaceutical and analytical development at Hoechst-Roussel Pharmaceuticals, Inc., predecessor companies of Sanofi-Aventis Pharmaceuticals, Inc. Prior to that, Dr. Bergstrom worked in pharmaceutical development at CIBA-Geigy Pharmaceuticals, Inc.

"We are very pleased to welcome Dr. Bergstrom to the Antares team," said Paul K. Wotton, Ph.D., President and Chief Executive Officer. "David has a proven track record as a leader of product development teams and has worked on multiple FDA approved products including 505B2 drug/device combination programs. His broad product development expertise will help drive our pipeline initiative and insure that we continue to execute our programs aggressively and expedite future product launches such as Quick Shot™ testosterone and QS M."

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company has received marketing approval from the U.S. Food and Drug Administration for OTREXUP™ (methotrexate) injection for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Antares Pharma is also developing VIBEX® QS T for testosterone replacement therapy. The Company's technology platforms include VIBEX® disposable Medi-Jet, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® [somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX® epinephrine and several other products. Antares Pharma's partnership with Ferring includes Zomacton® hGH (somatropin) injection. In the U.S. Antares has received FDA approval for Gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company's reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted Medi-Jet and pen injector systems. The Company's corporate office and Product Development and Commercial Groups are located in Ewing, New Jersey.

Contacts

Investor: Antares Pharma, Inc. Jack Howarth, 609-359-3016 Vice President, Corporate Affairs [email protected]